Prevention and management of chemotherapy-induced diarrhea in patients with colorectal cancer: A consensus statement by the Canadian Working Group on Chemotherapy-Induced Diarrhea

Current Oncology

Volumn 14, Issue 1, 2007, Pages 13-20

  Maroun, Jean A ^a   Anthony, Lowell B ^b   Blais, Normand ^c   Burkes, Ronald ^d   Dowden, Scot D ^e   Dranitsaris, George ^f   Samson, Benoît ^g   Shah, Amil ^h   Thirlwell, Michael P ⁱ   Vincent, Mark D ^j   Wong, Ralph ^k  

^a OTTAWA REGIONAL CANCER CENTRE   (Canada)

^b LOUISIANA STATE UNIV MEDICAL CENTER   (United States)

^c NOTRE DAME HOSPITAL   (Canada)

^d PRINCESS MARGARET HOSPITAL   (Canada)

^e TOM BAKER CANCER CENTRE   (Canada)

^f Hôpital Charles Lemoyne ^*

^g HÔPITAL CHARLES LEMOYNE   (Canada)

^h UNIVERSITY OF BRITISH COLUMBIA   (Canada)

ⁱ MONTREAL GENERAL HOSPITAL   (Canada)

^j LONDON HEALTH SCIENCES CENTRE   (Canada)

^k ST BONIFACE GENERAL HOSPITAL   (Canada)

more..

Author keywords

5 FU; Chemotherapy; CID; Diarrhea; Irinotecan; Management; Octreotide; Prophylaxis

Indexed keywords

ANTIBIOTIC AGENT; BEVACIZUMAB; CAPECITABINE; DIPHENOXYLATE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; LOPERAMIDE; OCTREOTIDE; OXALIPLATIN; PACLITAXEL; PLACEBO; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TEGAFUR;

ARTICLE; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER SURGERY; CLINICAL PRACTICE; CLINICAL TRIAL; COLORECTAL CANCER; CONTINUOUS INFUSION; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DISEASE SEVERITY; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG MEGADOSE; DRUG METABOLISM; DRUG TOLERABILITY; HEALTH CARE COST; HOSPITALIZATION; HUMAN; MORBIDITY; OPTIMAL DRUG DOSE; RECOMMENDED DRUG DOSE; REHYDRATION; RISK FACTOR;

EID: 51649105187     PISSN: None     EISSN: 17187729     Source Type: Journal    
DOI: 10.3747/co.2007.96     Document Type: Article

References (54)

1. Chiara S, Nobile MT, Vincenti M, et al. Advanced colorectal cancer in the elderly: results of consecutive trials with 5-fluorouracil-based chemotherapy. Cancer Chemother Pharmacol 1998;42:336-40.
2. Kabbinavar F, Hurwitz HI, Fehrenbacher L, et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/ leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003;21:60-5.
3. Nobile MT, Sanguineti O, Chiara S, et al. Activity of high dose 24 hour 5-fluorouracil infusion plus L-leucovorin in advanced colorectal cancer. Anticancer Res 1998;18(1B):517-21.
4. Nogue M, Segui MA, Saigi E, et al. Protracted treatment with tegafur and low dose oral leucovorin in patients with advanced colorectal carcinoma. Cancer 1998;83:254-8.
5. Cunningham D, Pyrhonen S, James RD, et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colerectal cancer. Lancet 1998;352:1413-18.
6. Huang K, Vaughn DJ, Shaw LM, Recio A, Bonner HS, Haller DG. A phase II trial and pharmacokinetic analysis of 96-hour infusional paclitaxel in patients with metastatic colorectal cancer. Am J Clin Oncol 1998;21:548-52.
7. Rougier P, Van Cutsem E, Bajetta E, et al. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 1998;352:1407-12.
8. Saliba F, Hagipantelli R, Misset JL, et al. Pathophysiology and therapy of irinotecan-induced delayed-onset diarrhea in patients with advanced colorectal cancer: a prospective assessment. J Clin Oncol 1998;16:2745-51.
9. Scheithauer W, Komek GV, Raderer M, et al. Combined irinotecan and oxaliplatin plus granulocyte colony-stimulating factor in patients with advanced fluoropyrimidine/leucovorin-pretreated colorectal cancer. J Clin Oncol 1999;17:902-6.
10. Van Cutsem E, Pozzo C, Starkhammar H, et al. A phase II study of irinotecan alternated with five days bolus of 5-fluorouracil and leucovorin in first-line chemotherapy of metastatic colorectal cancer. Ann Oncol 1998;9:1199-204.
11. Tournigand C, Louvet C, Andre T, et al. FOLFIRI followed by FOLFOX or FOLFOX followed by FOLFIRI in metastatic colorectal cancer (MCRC): which is the best sequence? Safety and preliminary efficacy results of a randomized phase III study [abstract 949]. Proc Am Soc Clin Oncol 2000;11(suppl 4):43.
12. Andre T, Louvet C, Maindrault-Goebel F, et al. CPT-11 (irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer. Eur J Cancer 1999;35:1343-7.
13. Maindrault-Goebel F, de Gramont A, Louvet C, et al. High-dose intensity oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX 7). Eur J Cancer 2001; 37:1000-5.
14. Hochster HS, Welles L, Hart L, et al. Safety and efficacy of bevacizumab (BEV) when added to oxaliplatin/fluoropyrimidine (O/F) regimens as first-line treatment of metastatic colorectal cancer (MCRC): TREE 1 & 2 studies) [abstract 3515]. J Clin Oncol 2005;23(suppl):249.
15. Chiara S, Nobile MT, Gozza A, et al. Phase II study of weekly oxaliplatin and high-dose infusional 5-fluorouracil plus leucovorin in pretreated patients with metastatic colorectal cancer. Anticancer Res 2004;24:355-60.
16. Fernando N, Yu M, Morse M, et al. A phase II study of oxaliplatin, capecitabine and bevacizumab in the treatment of metastatic colorectal cancer [abstract 3556]. J Clin Oncol 2005; 23(suppl):260.
17. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2332-42.
18. Saliba F, Hagipantelli R, Misset JL, et al. Pathophysiology and therapy of irinotecan-induced delayed-onset diarrhea in patients with advanced colorectal cancer: a prospective assessment. J Clin Oncol 1998;16:2745-51.
19. Arbuckle RB, Huber SL, Zacker C. The consequences of diarrhea occurring during chemotherapy for colorectal cancer: a retrospective study. Oncologist 2000;5;250-9.
20. Petrelli N, Herrera L, Rustum Y, et al. A prospective randomized trial of 5-fluorouracil versus 5-fluorouracil and high-dose leucovorin versus 5-fluorouracil and methotrexate in previously untreated patients with advanced colorectal carcinoma. J Clin Oncol 1987;5:1559-65.
21. Petrelli N, Douglass HO Jr, Herrera L, et al. The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomized phase III trial. J Clin Oncol 1989;7:1419-26.
22. Dranitsaris G, Maroun J, Shah A. Estimating the cost of illness in colorectal cancer patients who were hospitalized for severe chemotherapy-induced diarrhea. Can J Gastroenterol 2005;19:83-7.
23. Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000;343:905-14.
24. Rothenberg ML, Meropol NJ, Poplin EA, Van Cutsem E, Wadler S. Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel. J Clin Oncol 2001;19:3801-7.
25. Dranitsaris G, Tran TM. Economic analyses of toxicity secondary to anthracycline-based breast cancer chemotherapy. Eur J Cancer 1995;31A:2174-80.
26. Wadler S, Benson AB 3rd, Engelking C, et al. Recommended guidelines for the treatment of chemotherapy-induced diarrhea. J Clin Oncol 1998;16:3169-78.
27. Benson AB 3rd, Ajani JA, Catalano RB, et al. Recommended guidelines for the treatment of cancer treatment-induced diarrhea. J Clin Oncol 2004;22:2918-26.
28. Figueredo A, Moore M, Germond C, Kocha W, Maroun J, Zwaal C, and the Gastointestinal Cancer Disease Site Group. Use of irinotecan in the second-line treatment of metastatic colorectal carcinoma [online]. Practice Guideline Report #2-16. Toronto: Cancer Care Ontario; 2004. [Available at: www.guideline.gov/summary/ summary.aspx?ss=15&doc_id=7360&nbr=4358; cited August 2005]
29. National Cancer Institute, U.S. National Institutes of Health. Common terminology criteria for adverse events [online]. Ver. 3.0. December 12, 2003. [Formerly available at: ctep.cancer.gov/reporting/ctcnew.html; cited May 31, 2006]
30. Cascinu S, Barni S, Labianca R, et al. Evaluation of factors influencing 5-fluorouracil-induced diarrhea in colorectal cancer patients. An Italian Group for the Study of Digestive Tract Cancer (GISCAD) study. Support Care Cancer 1997;5:314-17.
31. Stein BN, Petrelli NJ, Douglass HO, Driscoll DL, Arcangeli G, Meropol NJ. Age and sex are independent predictors of 5-fluorouracil toxicity. Analysis of a large scale phase III trial. Cancer 1995;75:11-17.
32. Sloan JA, Goldberg RM, Sargent DJ, et al. Women experience greater toxicity with fluorouracil-based chemotherapy for colorectal cancer. J Clin Oncol 2002;20:1491-8.
33. Dranitsaris G, Maroun J, Chiritescu G, Shah A, Thirlwell M. The development of a prediction tool for severe diarrhea in patients with colorectal cancer receiving chemotherapy. Support Palliat Cancer Care 2006;[in pres.
34. Katona C, Kralovanszky J, Rosta A, et al. Putative role of dihydropyrimidine dehydrogenase in the toxic side effect of 5-fluorouracil in colorectal cancer patients. Oncology 1998;55: 468-74.
35. Marcuello E, Altes A, Menoyo A, Del Rio E, Gomez-Pardo M, Baiget M. UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer. Br J Cancer 2004;91:678-82.
36. Innocenti F, Undevia SD, Iyer L, et al. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol 2004;22:1382-8.
37. Food and Drug Administration. Captosar (irinotecan HCl). Hepatic dysfunction, pancreatitis, UGT1A1. Final label. July 21, 2005. [online; NDA 20-571/S-024/S-027/S-028; available at: www.fda.gov/cder/ foi/label/2005/020571s024,027,028lbl.pdf, cited May 31, 2006]
38. Kornblau S, Benson AG, Catalano R, et al. Management of cancer treatment-related diarrhea: issues and therapeutic strategies. J Pain Symptom Manage 2000;19:118-29.
39. Dom J, Leyman R, Schuermans V, Brugmans J. Loperamide (R 18553), a novel type of antidiarrheal agent. Part 8: Clinical investigation. Use of a flexible dosage schedule in a double-blind comparison of loperamide with diphenoxylate in 614 patients suffering from acute diarrhea. Arzneimittelforschung 1974;24:1660-5.
40. Pelemans W, Vantrappen F. A double blind crossover comparison of loperamide with diphenoxylate in the symptomatic treatment of chronic diarrhea. Gastroenterology 1976;70: 1030-4.
41. Palmer KR, Corbett CL, Holdsworth CD. Double-blind cross-over study comparing loperamide, codeine and diphenoxylate in the treatment of chronic diarrhea. Gastroenterology 1980;79: 1272-5.
42. Lavo B, Stenstam M, Nielsen AL. Loperamide in treatment of irritable bowel syndrome - a double-blind placebo controlled study. Scand J Gastroenterol Suppl 1987;130:77-80.
43. Tijtgat GN, Meuwissen SG, Huibregtse K. Loperamide in the symptomatic control of chronic diarrhoea. Double-blind placebo-controlled study. Ann Clin Res 1975;7:325-30.
44. Abigerges D, Armand JP, Chabot GG, et al. Irinotecan (CPT-11) high-dose escalation using intensive high-dose loperamide to control diarrhea. J Natl Cancer Inst 1994;86:446-9.
45. Rougier P, Bugat R, Douillard JY, et al. Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy. J Clin Oncol 1997;15:251-60.
46. Cascinu S, Fedeli A, Fedeli SL, Catalano G. Octreotide versus loperamide in the treatment of fluorouracil-induced diarrhea: a randomized trial. J Clin Oncol 1993;11:148-51.
47. Gebbia V, Carreca I, Testa A, et al. Subcutaneous octreotide versus oral loperamide in the treatment of diarrhea following chemotherapy. Anticancer Drugs 1993;4:443-5.
48. Goumas P, Naxakis S, Christopoulou A, Chrysanthopoulos C, Nikolopoulou VV, Kalafonos HP. Octreotide acetate in the treatment of fluorouracil-induced diarrhea. Oncologist 1998; 3:50-3.
49. Yavuz MN, Yavuz AA, Aydin F, Can G, Kavgaci H. The efficacy of octreotide in the therapy of acute radiation-induced diarrhea: a randomized controlled study. Int J Radiat Oncol Biol Phys 2002;54:195-202.
50. Wadler S, Haynes H, Wiernik PH. Phase I trial of the somatostatin analog octreotide acetate in the treatment of fluoropyrimidine-induced diarrhea. J Clin Oncol 1995;13: 222-6.
51. Meropol NJ, Blumenson LE, Creaven PJ. Octreotide does not prevent diarrhea in patients treated with weekly 5-fluorouracil plus high-dose leucovorin. Am J Clin Oncol 1998;21:135-8.
52. Rosenoff SH. Octreotide LAR resolves severe chemotherapy-induced diarrhoea (CID) and allows continuation of full-dose therapy. Eur J Cancer Care (Engl) 2004;13:380-3.
53. Rosenoff SH. CID symptom resolution with long-acting octreotide depot [abstract 1545]. Proc Am Soc Clin Oncol 2002; 21:61.
54. National Cancer Institute, National Institutes of Health. Phase III randomized study of octreotide in preventing or reducing the severity of chemoradiotherapy-induced diarrhea in patients with anal or rectal cancer [online]. Bethesda: National Institutes of Health; n.d. [Available at: www.cancer.gov/clinicaltrials/RTOG-0315; cited November 14, 2005]